MET targeted therapy for lung cancer: clinical development and future directions
Yan Feng,1,2 Patrick C Ma1–31Translational Hematology and Oncology Research, 2Solid Tumor Oncology, 3Aerodigestive Oncology Translational Research, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USAAbstract: MET, the receptor for hepatocyte growth factor, has been identified...
Guardado en:
Autores principales: | Feng Y, Ma PC |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1198cbd4fa954096b42e0400a73a3c59 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
MET overexpression and gene amplification in NSCLC: a clinical perspective
por: Landi L, et al.
Publicado: (2013) -
Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
por: Dana S. Neel, et al.
Publicado: (2017) -
Non-small cell lung cancer: the era of targeted therapy
por: Antonoff MB, et al.
Publicado: (2012) -
Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future
por: Razan Alzeibak, et al.
Publicado: (2021) -
Correction: Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future
Publicado: (2021)